Archaeosome Adjuvant Overcomes Tolerance to Tumor-Associated Melanoma Antigens Inducing Protective CD8+T Cell Responses
Open Access
- 1 January 2010
- journal article
- research article
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2010, 1-13
- https://doi.org/10.1155/2010/578432
Abstract
Vesicles comprised of the ether glycerolipids of the archaeonMethanobrevibacter smithii(archaeosomes) are potent adjuvants for evoking CD8+T cell responses. We therefore explored the ability of archaeosomes to overcome immunologic tolerance to self-antigens. Priming and boosting of mice with archaeosome-antigen evoked comparable CD8+T cell response and tumor protection to an alternate boosting strategy utilizing live bacterial vectors for antigen delivery. Vaccination with melanoma antigenic peptides TRP181-189and Gp10025-33delivered in archaeosomes resulted in IFN-γproducing antigen-specific CD8+T cells with strong cytolytic capability and protection against subcutaneous B16 melanoma. Targeting responses against multiple antigens afforded prolonged median survival against melanoma challenge. Entrapment of multiple peptides within the same vesicle or admixed formulations were both effective at evoking CD8+T cells against each antigen. Melanoma-antigen archaeosome formulations also afforded therapeutic protection against established B16 tumors when combined with depletion of T-regulatory cells. Overall, we demonstrate that archaeosome adjuvants constitute an effective choice for formulating cancer vaccines.Keywords
Funding Information
- Ontario Institute for Cancer Research
This publication has 46 references indexed in Scilit:
- Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidityVaccine, 2010
- Highly selective fusion and accumulation of hybrid liposomes into primary effusion lymphoma cells along with induction of apoptosisBiochemical and Biophysical Research Communications, 2010
- Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor EffectsCancer Research, 2009
- Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cellsAnnals of the New York Academy of Sciences, 2009
- IFN-α Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor ActivityThe Journal of Immunology, 2009
- Prophylaxis with cationic liposome–DNA complexes protects hamsters from phleboviral disease: Importance of liposomal delivery and CpG motifsAntiviral Research, 2009
- The quality control of MHC class I peptide loadingCurrent Opinion in Cell Biology, 2008
- Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and MechanismsClinical Cancer Research, 2006
- Programming CD8+ T cells for effective immunotherapyCurrent Opinion in Immunology, 2006
- A structural comparison of the total polar lipids from the human archaea Methanobrevibacter smithii and Methanosphaera stadtmanae and its relevance to the adjuvant activities of their liposomesBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1999